Trinity Biotech plc

NasdaqGS:TRIB Stock Report

Market Cap: US$14.4m

Trinity Biotech Management

Management criteria checks 2/4

Trinity Biotech's CEO is John Gillard, appointed in Nov 2020, has a tenure of 5.25 years. total yearly compensation is $975.00K, comprised of 69.3% salary and 30.7% bonuses, including company stock and options. directly owns 0.053% of the company’s shares, worth $7.70K. The average tenure of the management team and the board of directors is 10.4 years and 3.3 years respectively.

Key information

John Gillard

Chief executive officer

US$975.0k

Total compensation

CEO salary percentage69.33%
CEO tenure5.3yrs
CEO ownership0.05%
Management average tenure10.4yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Trinity Biotech plc (NASDAQ:TRIB) Held Back By Insufficient Growth Even After Shares Climb 54%

Dec 24
Trinity Biotech plc (NASDAQ:TRIB) Held Back By Insufficient Growth Even After Shares Climb 54%

Trinity Biotech plc's (NASDAQ:TRIB) Share Price Boosted 54% But Its Business Prospects Need A Lift Too

Dec 24
Trinity Biotech plc's (NASDAQ:TRIB) Share Price Boosted 54% But Its Business Prospects Need A Lift Too

Investors Still Aren't Entirely Convinced By Trinity Biotech plc's (NASDAQ:TRIB) Revenues Despite 37% Price Jump

May 01
Investors Still Aren't Entirely Convinced By Trinity Biotech plc's (NASDAQ:TRIB) Revenues Despite 37% Price Jump

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 70% But It Can Do More

Jan 29
The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 70% But It Can Do More

Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

Sep 25
Investors Give Trinity Biotech plc (NASDAQ:TRIB) Shares A 38% Hiding

A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

Aug 07
A Piece Of The Puzzle Missing From Trinity Biotech plc's (NASDAQ:TRIB) 35% Share Price Climb

The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Jun 11
The Market Lifts Trinity Biotech plc (NASDAQ:TRIB) Shares 34% But It Can Do More

Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Mar 02
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%

Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

Dec 18
Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry

A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Sep 12
A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)

Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Aug 08
Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?

Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Jun 09
Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price

Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

Apr 23
Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)

This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Apr 23
This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts

Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

Mar 01
Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has John Gillard's remuneration changed compared to Trinity Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$36m

Jun 30 2025n/an/a

-US$36m

Mar 31 2025n/an/a

-US$37m

Dec 31 2024US$975kUS$676k

-US$31m

Sep 30 2024n/an/a

-US$20m

Jun 30 2024n/an/a

-US$22m

Mar 31 2024n/an/a

-US$34m

Dec 31 2023US$710kUS$473k

-US$37m

Sep 30 2023n/an/a

-US$39m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$34m

Dec 31 2022US$863kUS$452k

-US$44m

Sep 30 2022n/an/a

-US$32m

Jun 30 2022n/an/a

-US$22m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$593kUS$346k

-US$2m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$2m

Mar 31 2021n/an/a

-US$2m

Dec 31 2020US$312kUS$52k

-US$6m

Compensation vs Market: John's total compensation ($USD975.00K) is above average for companies of similar size in the US market ($USD577.67K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Gillard (43 yo)

5.3yrs
Tenure
US$975,000
Compensation

Mr. John Gillard is President & CEO of Trinity Biotech plc since December 17, 2023 and served as Chief Financial Officer since November 17, 2020 until December 17, 2023. He serves as Executive Director at...

Leadership Team

NamePositionTenureCompensationOwnership
John Gillard
President5.3yrsUS$975.00k0.053%
$ 7.7k
Ronan O'Caoimh
Founder33.7yrsUS$84.00k2.6%
$ 374.4k
James Walsh
Executive Director of Business Development & Executive Directorno dataUS$83.00k0.37%
$ 53.7k
Jacqueline O'Neill
Director of Operationsno datano datano data
Gary Keating
Chief Technology Officerno datano datano data
Eibhlin Kelly
Chief Information Officer10.4yrsno datano data
Colm Molloy
Group Director of Human Resources & Cultureno datano datano data
10.4yrs
Average Tenure
52yo
Average Age

Experienced Management: TRIB's management team is seasoned and experienced (10.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Gillard
President5.3yrsUS$975.00k0.053%
$ 7.7k
Ronan O'Caoimh
Founder3.3yrsUS$84.00k2.6%
$ 374.4k
James Walsh
Executive Director of Business Development & Executive Director19.1yrsUS$83.00k0.37%
$ 53.7k
Paul Tivnan
Non-Executive Directorless than a yearno datano data
Andrew Omidvar
Independent Director2.4yrsUS$57.00k0%
$ 0
3.3yrs
Average Tenure
67yo
Average Age

Experienced Board: TRIB's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/17 22:16
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Trinity Biotech plc is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura McGuiganB. Riley Securities, Inc.
Lawrence SolowCJS Securities, Inc.
William BonelloCraig-Hallum Capital Group LLC